IRB #

STUDY00016070

Title

A Phase 1B Study of Ribociclib in Combination with Doxorubicin in Advanced Soft Tissue Sarcomas

Principal Investigator

Lara Davis

Study Purpose

The purpose of this study is to test the safety and test any side effects, good or bad, that ribociclib (the study drug) has when used in combination with doxorubicin on participants with advanced soft tissue sarcoma.

Medical Condition(s)

Soft tissue sarcoma

Eligibility Criteria

15 years or older with metastatic or unresectable soft tissue sarcoma.

Further tests, procedures, and review of medical history will be done to confirm eligibility.

Age Range

15 - 120

Healthy Volunteers Needed

No

Duration of Participation

The study drug and doxorubicin for up to 4 months and then the study drug by itself for as long as you are seeing benefit.

Minors Included

Yes

Contact

Knight Clinical Trials Office
trials@ohsu.edu

Sponsor

Oregon Health & Science University

Recruitment End

05/30/2018

Compensation Provided

No


Go Back